Analysis of normal-tumour tissue interaction in tumours: Prediction of prostate cancer features from the molecular profile of adjacent normal cells

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Trevino, Victor ^a,e   Tadesse, Mahlet G ^b   Vannucci, Marina ^c   Al Shahrour, Fatima ^d   Antczak, Philipp ^a   Durant, Sarah ^a   Bikfalvi, Andreas ^g,h   Dopazo, Joaquin ^d   Campbell, Moray J ^a,f   Falciani, Francesco ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c RICE UNIVERSITY   (United States)

^d CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^e SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g INSERM   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSINOGEN; FRACTALKINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; JAGGED1; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; GROWTH FACTOR RECEPTOR; SIGNAL PEPTIDE;

ARTICLE; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CYTOLOGY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROSTATE CANCER; STATISTICAL MODEL; TISSUE INTERACTION; ANTIBODY SPECIFICITY; CELL COMMUNICATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; MALE; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROSTATE; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL COMMUNICATION; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; ORGAN SPECIFICITY; PRINCIPAL COMPONENT ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79953301178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016492     Document Type: Article

References (57)

1. Gregg JL, Brown KE, Mintz EM, Piontkivska H, Fraizer GC, (2010) Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 10: 165.
2. Quackenbush J, (2006) Microarray analysis and tumor classification. N Engl J Med 354: 2463-2472.
3. Alberti C, (2006) Prostate cancer progression and surrounding microenvironment. Int J Biol Markers 21: 88-95.
4. Rollins BJ, (2006) Inflammatory chemokines in cancer growth and progression. Eur J Cancer 42: 760-767.
5. Joshi A, Cao D, (2010) TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci 15: 180-194.
6. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
8. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101: 811-816.
9. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, et al. (2002) Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209.
10. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5: 45.
11. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
12. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, et al. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226.
13. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, et al. (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15: 35-44.
14. Campos AH, Wang W, Pollman MJ, Gibbons GH, (2002) Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ Res 91: 999-1006.
15. Hinz M, Lemke P, Anagnostopoulos I, Hacker C, Krappmann D, et al. (2002) Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196: 605-617.
16. Hinata K, Gervin AM, Jennifer Zhang Y, Khavari PA, (2003) Divergent gene regulation and growth effects by NF-kappa B in epithelial and mesenchymal cells of human skin. Oncogene 22: 1955-1964.
17. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, et al. (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 100: 2645-2650.
18. Lindmark F, Zheng SL, Wiklund F, Balter KA, Sun J, et al. (2005) Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 93: 493-497.
19. Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A, (2004) CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698.
20. Wang D, Wang H, Brown J, Daikoku T, Ning W, et al. (2006) CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203: 941-951.
21. Wang W, Li Y, Hong A, Wang J, Lin B, et al. (2009) NDRG3 is an androgen regulated and prostate enriched gene that promotes in vitro and in vivo prostate cancer cell growth. Int J Cancer 124: 521-530.
22. Ghadjar P, Loddenkemper C, Coupland SE, Stroux A, Noutsias M, et al. (2008) Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol 134: 1181-1189.
23. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, et al. (2009) Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28: 3390-3400.
24. Jeay S, Pianetti S, Kagan HM, Sonenshein GE, (2003) Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23: 2251-2263.
25. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, et al. (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res 69: 6685-6693.
26. Larsson O, Girnita A, Girnita L, (2005) Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 92: 2097-2101.
27. Vlahos CJ, Kriauciunas TD, Gleason PE, Jones JA, Eble JN, et al. (1993) Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells. J Cell Biochem 52: 404-413.
28. Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, et al. (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 117: 2766-2777.
29. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, et al. (1994) Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 93: 1266-1274.
30. Dupont J, Khan J, Qu BH, Metzler P, Helman L, et al. (2001) Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142: 4969-4975.
31. Tullai JW, Schaffer ME, Mullenbrock S, Kasif S, Cooper GM, (2004) Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways. J Biol Chem 279: 20167-20177.
32. Tsai MS, Bogart DF, Castaneda JM, Li P, Lupu R, (2002) Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21: 8178-8185.
33. Menendez JA, Mehmi I, Griggs DW, Lupu R, (2003) The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 10: 141-152.
34. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y, et al. (2004) Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 61: 305-317.
35. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, et al. (2008) Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 99: 1656-1667.
36. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, et al. (2008) CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323-7331.
37. Bierie B, Moses HL, (2010) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21: 49-59.
38. Gaengel K, Genove G, Armulik A, Betsholtz C, (2009) Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29: 630-638.
39. Ding Q, Bai YF, Wang YQ, An RH, (2010) TGF-beta1 reverses inhibition of COX-2 with NS398 and increases invasion in prostate cancer cells. Am J Med Sci 339: 425-432.
40. Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, et al. (2010) VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 316: 554-567.
41. Chow L, Rezmann L, Catt KJ, Louis WJ, Frauman AG, et al. (2009) Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol 302: 219-229.
42. Uemura H, Ishiguro H, Ishiguro Y, Hoshino K, Takahashi S, et al. (2008) Angiotensin II induces oxidative stress in prostate cancer. Mol Cancer Res 6: 250-258.
43. Bose SK, Gibson W, Giri S, Nath N, Donald CD, (2009) Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor. Prostate 69: 1334-1342.
44. Uemura H, Ishiguro H, Kubota Y, (2006) Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 6: 835-844.
45. Uemura H, Ishiguro H, Kubota Y, (2008) Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 15: 19-26.
46. Roca C, Adams RH, (2007) Regulation of vascular morphogenesis by Notch signaling. Genes Dev 21: 2511-2524.
47. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, et al. (2004) JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64: 6854-6857.
48. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
49. Schroder FH, Roobol MJ, Andriole GL, Fleshner N, (2009) Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 181: 69-74; discussion 74.
50. Cianfrocca M, Gradishar W, (2009) New molecular classifications of breast cancer. CA Cancer J Clin 59: 303-313.
51. Sun Y, Goodison S, (2009) Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 69: 1119-1127.
52. Redner A, Melamed MR, Andreeff M, (1986) Detection of central nervous system relapse in acute leukemia by multiparameter flow cytometry of DNA, RNA, and CALLA. Ann N Y Acad Sci 468: 241-255.
53. Montaner D, Tarraga J, Huerta-Cepas J, Burguet J, Vaquerizas JM, et al. (2006) Next station in microarray data analysis: GEPAS. Nucleic Acids Res 34: W486-491.
54. Ooi CH, Tan P, (2003) Genetic algorithms applied to multi-class prediction for the analysis of gene expression data. Bioinformatics 19: 37-44.
55. Trevino V, Falciani F, (2006) GALGO: an R package for multivariate variable selection using genetic algorithms. Bioinformatics 22: 1154-1156.
56. Sha N, Vannucci M, Tadesse MG, Brown PJ, Dragoni I, et al. (2004) Bayesian variable selection in multinomial probit models to identify molecular signatures of disease stage. Biometrics 60: 812-819.
57. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 microarray software suite. Methods Enzymol 411: 134-193.